Collectionner le produit
Détails du produit
Synonyms
Integrin alpha V beta 6, ITGAV&ITGB6
Source
Biotinylated Human ITGAV&ITGB6 Heterodimer Protein, His,Avitag&Tag Free (IT6-H82E4) is expressed from human 293 cells (HEK293). It contains AA Phe 31 - Val 992 (ITGAV) & Gly 22 - Asn 707 (ITGB6) (Accession # NP_002201.1 (ITGAV) & AAI21179.1 (ITGB6)).
Predicted N-terminus: Phe 31 (ITGAV) & Gly 22 (ITGB6)
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
Biotinylated Human ITGAV&ITGB6 Heterodimer Protein, His,Avitag&Tag Free, produced by co-expression of ITGAV and ITGB6, has a calculated MW of 114.7 kDa (ITGAV) and 79.6 kDa (ITGB6). Subunit ITGAV is fused with an acidic tail at the C-terminus and followed by a polyhistidine tag and an Avi tag (Avitag™) and subunit ITGB6 contains no tag but a basic tail at the C-terminus. The predicted N-terminus is Phe 31 (ITGAV) & Gly 22 (ITGB6). The non-reducing (NR) protein migrates as 135-150 kDa (ITGAV) and 82-95 kDa (ITGB6) respectively due to glycosylation.
Labeling
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Protein Ratio
Passed as determined by the HABA assay / binding ELISA.
Purity
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE
Biotinylated Human ITGAV&ITGB6 Heterodimer Protein, His,Avitag&Tag Free on SDS-PAGE under non-reducing (NR) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
SEC-MALS
The purity of Biotinylated Human ITGAV&ITGB6 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT6-H82E4) is more than 90% and the molecular weight of this protein is around 200-235 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Human Latent TGFB1, His Tag (Cat. No. TG1-H524x) at 5 μg/mL (100 μL/well) can bind Biotinylated Human ITGAV&ITGB6 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT6-H82E4) with a linear range of 5-39 ng/mL (QC tested).
Protocol
Immobilized Fibronectin at 10 μg/mL (100 μL/well) can bind Biotinylated Human ITGAV&ITGB6 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT6-H82E4) with a linear range of 0.078-1.25 μg/mL (Routinely tested).
Protocol
Immobilized Human LRRC32&TGFB1 Heterotrimer protein, His Tag&Tag Free (Cat. No. GA1-H52W9) at 1 μg/mL (100 μL/well) can bind Biotinylated Human ITGAV&ITGB6 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT6-H82E4) with a linear range of 2-39 ng/mL (Routinely tested).
Protocol
Avis des utilisateurs Publier un commentaire
A***l2022-03-15
J'aimeGreat communication from the Acro team--quickly received an email detailing the estimated delivery timeframe and asking if that timeframe was acceptable. Product was ready per the timeline provided by the Acro biosystems team and shipped. This was a new product for us (though we’ve used other acro biosystems products previously) and worked well for our intended use with Surface Plasmon Resonance (SPR). Thank you all!
Introduction de fond
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
Integrin alpha-V/beta-6
- Catégorie：
- Nombre de médicaments répertoriés：
0 Détails
- Nombre de médicaments cliniques：
6 Détails
- Étape de développement la plus élevée：
Phase 2 Clinical
Contact Us
Drug Candidate Licensing
